EBRDA
data caveat$277M12mo
EBR Systems
Medical Devices · Cardiac
WiSE wireless cardiac pacing system for heart failure
Data HealthTrials4 of 4 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$54.2M
Dec 2025 4C
Runway
12moADEQUATE
Based on Dec 2025 4C
Market Cap
$277M
Burn Rate
$13.3M/qtr
Dec 2025 4C
Shares Outstanding
450M
Pipeline Assets
1
Latest Insight(1)
30 Mar 2026Annual ReportCorrection of Annual Report
Cash$54.2M·Burn$53.2M/q·OCF$-53.2M
3M Price
EBRDA.ASX$0.670-30.6% 3M
Low $0.580High $0.965
Pipeline Assets (1)
WiSE CRTHeart failure / CRT
Phase 3Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
WiSE CRT
Heart failure / CRT
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
1 transactionLast 90dNo Activity
Buys0
Sells0
OPTIONS EXERCISEJohn McCutcheonopen_in_new
2026-03-24
37d before · Potential capital raise
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
0.01%
arrow_drop_down0.00% over 30 reports
Shares short
0.0M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
6 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Front Cardiovasc Med2026-01· WiSE CRT
Curr Cardiol Rep2025-12· WiSE CRT
Herzschrittmacherther Elektrophysiol2025-12· WiSE CRT
Catalysts (5)· 4 upcoming · 1 past
WiSE CRT pivotal trial enrolment complete
UpcomingExpectedarrow_upwardHigh30 June 2026
SpeculativeremoveMed1 Apr 2027
SpeculativeMed
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High100/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 5 tracked
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
What drove these scores · rolling 2yr
arrow_drop_up
Stable burn rate — 8% quarterly variation — consistent spend
arrow_drop_up
Cash position improving — Cash balance grew over last 3 quarters
arrow_drop_up
R&D-focused spend — 82% of opex directed to R&D
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Completed catalysts
✓Potential capital raise— Cash position improved from $13.8M to $54.2M across Q2-Q4 2025 (raises occurred but not yet recorded in capital_raise table)
304d early
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(5)
4 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 170d
The Wise System
The WiSE®-UP Registry (The WiSE System Utilization & Performance Registry)
Heart Failure
Primary endpoint Primary Safety
NARecruitingEnrollment stale · 125d
WiSE CRT System
A Feasibility Study Implant of the WiSE® CRT System With an Intracardiac Pacemaker to Achieve Totally Leadless CRT
Heart Failure
22 Years+
Primary endpoint Incidence of Device and procedure related complications.
Active Not RecruitingOBSERVATIONALEnrollment stale · 3726d
WiCS-LV System
WiCS-LV Post Market Surveillance Registry
Cardiac Resynchronization Therapy
18 Years+
Primary endpoint Complications
Announcements(14)
description
Quarterly ActivitiesPS
EBR Reports Strong Q1 2026 Growth in Commercial Cases8 Apr 2026
405KB